Dermatitis. 2010;21(1):59-60 ... nystatin powder, A+D Ointment (Schering-Plough Kenilworth, NJ), and three different topical clotrimazole creams, with no improvement. Several vaginal potassium ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

and mupirocin ointment. Patch testing with the North American Contact Dermatitis Group (NACDG) standard tray, corticosteroids, vehicles, preservatives, flavorings, corticosteroids, cosmetics ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Both body creams and lotions hydrate skin, but they have a few key differences. The main is consistency. Here’s how to tell ...

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Organon (NYSE: OGN), a global healthcare company with a ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...